Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.
Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, Yoshimi A, Ogata-Kawata H, Sakamoto H, Kato M, Fukushima K, Hasegawa D, Fukushima H, Imai M, Kajiwara R, Koike T, Komori I, Matsui A, Mori M, Moriwaki K, Noguchi Y, Park MJ, Ueda T, Yamamoto S, Matsuda K, Yoshida T, Matsumoto K, Hata K, Kubo M, Matsubara Y, Takahashi H, Fukushima T, Hayashi Y, Koh K, Manabe A, Ohara A; Tokyo Children’s Cancer Study Group (TCCSG). Ohki K, et al. Among authors: imai m. Haematologica. 2019 Jan;104(1):128-137. doi: 10.3324/haematol.2017.186320. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171027 Free PMC article. Clinical Trial.
A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.
Gocho Y, Kiyokawa N, Ichikawa H, Nakabayashi K, Osumi T, Ishibashi T, Ueno H, Terada K, Oboki K, Sakamoto H, Shioda Y, Imai M, Noguchi Y, Arakawa Y, Kojima Y, Toyama D, Hata K, Yoshida T, Matsumoto K, Kato M, Fukushima T, Koh K, Manabe A, Ohara A; Tokyo Children’s Cancer Study Group. Gocho Y, et al. Among authors: imai m. Leukemia. 2015 Dec;29(12):2445-8. doi: 10.1038/leu.2015.111. Epub 2015 May 6. Leukemia. 2015. PMID: 25943178 No abstract available.
Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team.
Tsuji Y, Imai K, Kajiwara M, Aoki Y, Isoda T, Tomizawa D, Imai M, Ito S, Maeda H, Minegishi Y, Ohkawa H, Yata J, Sasaki N, Kogawa K, Nagasawa M, Morio T, Nonoyama S, Mizutani S. Tsuji Y, et al. Among authors: imai m, imai k. Bone Marrow Transplant. 2006 Mar;37(5):469-77. doi: 10.1038/sj.bmt.1705273. Bone Marrow Transplant. 2006. PMID: 16435016
Obesity and febrile urinary tract infection in young children.
Okada M, Kijima E, Yamamura H, Nakatani H, Yokoyama H, Imai M, Suzuki N, Oshiba A, Nagasawa M. Okada M, et al. Among authors: imai m. Pediatr Int. 2022 Jan;64(1):e14686. doi: 10.1111/ped.14686. Epub 2021 Oct 15. Pediatr Int. 2022. PMID: 33682248
An eight-year-old girl with autoimmune polyglandular syndrome type3A that developed during the course of primary Epstein-Barr virus (EBV) infection: clinical implication of EBV in autoimmune thyroid disease.
Kirino S, Nakatani H, Honma A, Shinbo A, Onda K, Okada M, Imai M, Suzuki N, Oshiba A, Nagasawa M. Kirino S, et al. Among authors: imai m. Immunol Med. 2020 Mar;43(1):57-60. doi: 10.1080/25785826.2019.1701365. Epub 2019 Dec 18. Immunol Med. 2020. PMID: 31852362
Affinity-directed substrate/H+-antiport by a MATE transporter.
Takeuchi K, Ueda T, Imai M, Fujisaki M, Shimura M, Tokunaga Y, Kofuku Y, Shimada I. Takeuchi K, et al. Among authors: imai m. Structure. 2024 May 18:S0969-2126(24)00181-3. doi: 10.1016/j.str.2024.05.004. Online ahead of print. Structure. 2024. PMID: 38815577
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, Soldà C, Piscaglia F, Tosetti G, Marra F, Vivaldi C, Conti F, Schirripa M, Iwamoto H, Sho T, Lee SH, Rizzato MD, Tonnini M, Rimini M, Campani C, Masi G, Foschi F, Bruccoleri M, Kawaguchi T, Kumada T, Hiraoka A, Atsukawa M, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Kawata K, Tada F, Ohama H, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Casadei-Gardini A, Lampertico P. Iavarone M, et al. Among authors: imai m. Liver Cancer. 2023 Sep 14;13(2):215-226. doi: 10.1159/000534127. eCollection 2024 Apr. Liver Cancer. 2023. PMID: 38751557 Free PMC article.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: imai m. Aliment Pharmacol Ther. 2024 May 8. doi: 10.1111/apt.18037. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38716823
1,704 results